These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 1403119)

  • 1. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
    Holladay FP; Heitz T; Wood GW
    J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells.
    Holladay FP; Lopez G; De M; Morantz RA; Wood GW
    Neurosurgery; 1992 Apr; 30(4):499-504; discussion 504-5. PubMed ID: 1584347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes.
    Holladay FP; Heitz T; Chen YL; Chiga M; Wood GW
    Neurosurgery; 1992 Sep; 31(3):528-33. PubMed ID: 1407433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
    Kruse CA; Lillehei KO; Mitchell DH; Kleinschmidt-DeMasters B; Bellgrau D
    Proc Natl Acad Sci U S A; 1990 Dec; 87(24):9577-81. PubMed ID: 2263613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
    Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
    Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of cytotoxic immune responses during the progression of a rat glioma.
    Holladay FP; Choudhuri R; Heitz T; Wood GW
    J Neurosurg; 1994 Jan; 80(1):90-6. PubMed ID: 8271027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of cellular immune responses against a glioma-associated antigen(s).
    Holladay FP; Wood GW
    J Neuroimmunol; 1993 Apr; 44(1):27-32. PubMed ID: 8496337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Infiltrative and cytolytic activities of lymphokine-activated killer (LAK) cells against a human glioma mass: ultrastructural analysis using a three-dimensional multicellular spheroid model].
    Iwasaki K
    Nihon Geka Hokan; 1990 Jan; 59(1):39-54. PubMed ID: 2130768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rat mitogen-stimulated lymphokine-activated T killer cells: production and effects on C6 glioma cells in vitro and in vivo in the brain of Wistar rats.
    Carson WE; Jakowatz JG; Yamamoto R; Fitzgerald T; Gupta S; Vayuvegula B; Lucci JA; Beckman MT; Dulkanchainun S; Granger GA
    J Immunother (1991); 1991 Apr; 10(2):131-40. PubMed ID: 2043593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
    Yoshida S; Tanaka R; Takai N; Ono K
    Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2.
    Glick RP; Lichtor T; de Zoeten E; Deshmukh P; Cohen EP
    Neurosurgery; 1999 Oct; 45(4):867-74. PubMed ID: 10515482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
    Takai N; Tanaka R; Yoshida S; Hara N; Saito T
    Cancer Res; 1988 Apr; 48(8):2047-52. PubMed ID: 3258182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
    Yoshida S; Takai N; Ono K; Saito T; Tanaka R
    No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells].
    Nitta T; Ishizawa A; Ito M; Sato K; Yagita H; Kumura K
    No Shinkei Geka; 1990 Nov; 18(11):1001-6. PubMed ID: 2247192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The anti-tumor efficacy of lymphokine-activated killer (LAK) cells induced in vitro from peripheral blood lymphocytes of patients with malignant glioma].
    Shimizu K; Miyao Y; Okamoto Y; Matsui Y; Ushio Y; Tsuda N; Hayakawa T; Ishida N; Mogami H
    No To Shinkei; 1986 Mar; 38(3):265-71. PubMed ID: 3085695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive cell transfer therapy for malignant gliomas.
    Ishikawa E; Takano S; Ohno T; Tsuboi K
    Adv Exp Med Biol; 2012; 746():109-20. PubMed ID: 22639163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes.
    Rice CD; Baldwin NG; Biron RT; Bear HD; Merchant RE
    J Neurooncol; 1997 Mar; 32(1):29-38. PubMed ID: 9049860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphokine-activated killer (LAK) cell purging of bone marrow.
    Cramer DV; Long GS
    Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.